SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue
SpectraCure AB’s (publ) (Nasdaq First North Premier Growth Market: SPEC) (“SpectraCure” or the “Company”) fully guaranteed new Units issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), was fully subscribed. Through the Rights Issue, SpectraCure will receive proceeds amounting to approximately SEK 140 million before transaction costs. Not for publication, distribution or […]
Wider range of prospective patients in the UK, Canada and the US for continued clinical study
As previously disclosed, the US authority FDA has approved SpectraCure's new and revised study protocol for the clinical study on patients with recurrent prostate cancer. The protocol has also been approved by the UK and Canadian authorities. The new protocol expands the inclusion criteria for Gleason score, which allows a wider range of candidates to […]
A future alternative to hormonal treatment for prostate cancer
At this year's cancer congress in Chicago (ASCO), novel hormone treatments of patients suffering from non-metastatic castration-resistant prostate cancer were recognized. There are currently no efficient treatment options for the condition. Prostate cancer is the most common form of cancer in the western world. Every year, approximately 600,000 new cases are diagnosed in the US […]
Subscription period postponed for the rights issue. Other conditions remain unchanged
SpectraCure AB (publ) postpones the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. All other terms and conditions of the rights issue remain unchanged. The Board of Directors of SpectraCure AB (publ) has resolved to postpone […]
Patent application submitted to protect new technology
SpectraCure has submitted a new patent application to the European Patent Office. The patent application regards the technical solution used in the new generation of SpectraCure's treatment system. The technology makes it possible to use the same optical fiber for both treatment and dose monitoring; together with the IDOSE software, this is what makes the […]
SpectraCure’s MSEK 140 rights issue of units is fully guaranteed
THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, JAPAN, CANADA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTION. A top guarantee up to 100 percent of the rights issue has been […]
SpectraCure AB Quarterly Report (1 Jan to 31 March) 2020
Please note that the attached report is in Swedish. First quarter 2020 The figures for 2020 and 2019 refer to the Group. Other operating income amounted to SEK 1,185 (650) thousand Profit after tax amounted to SEK -3,784 (-2,776) thousand Earnings per share before and after dilution: SEK -0.04 (-0.03) Cash flow from operating activities […]
Patent application enters PCT phase, SpectraCure ensures development and work
SpectraCure’s work and development proceeds with several parallel projects. A patent application which covers a new technology that improves upon the Company’s IDOSE technology is now progressing to the so-called PCT phase, which is a way of coordinating patent applications in all the countries of the world. This is a result of the positive outcome […]
New study underway in the US and approval from the Food and Drug Administration (FDA)
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment. – I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan […]
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020
Refers to the latest travel information regarding the United States. The scheduled meeting, "Site Initiation Visit", between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, will be conducted tomorrow Friday. It is a formal meeting for the start-up and review of procedures and equipment. After the meeting is completed, the study is underway and recruitment of […]
